Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats-Reference-Cited by-同舟云学术

Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats

Published:2017-03-27 Issue:4 Volume:44 Page:522-525
ISSN:0305-1870
Container-title:Clinical and Experimental Pharmacology and Physiology
language:en
Short-container-title:Clin Exp Pharmacol Physiol

Author:

Rahman Asadur¹,Fujisawa Yoshihide²,Nakano Daisuke¹,Hitomi Hirofumi¹,Nishiyama Akira¹^ORCID

Affiliation:

1. Department of Pharmacology; Faculty of Medicine; Kagawa University; Kagawa Japan

2. Life Science Research Center; Faculty of Medicine; Kagawa University; Kagawa Japan

Funder

Japan Society for the Promotion of Science London

Publisher

Wiley

Subject

Physiology (medical),Pharmacology,Physiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1440-1681.12725/fullpdf

Reference25 articles.

1. Metabolic syndrome as a cardiovascular disease risk factor: patients evaluated in primary care;Cabre;BMC Public Health,2008

2. Circadian rhythms and metabolic syndrome: from experimental genetics to human disease;Maury;Circ Res,2010

3. Circadian misalignment increases cardiovascular disease risk factors in humans;Morris;Proc Natl Acad Sci USA,2016

4. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials;Monami;Acta Diabetol,2017

5. Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with Type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials;Sakai;Clin Ther,2016

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium–Glucose Cotransporter Protein 2 Inhibitors: Novel Application for the Treatment of Obesity-Associated Hypertension;Diabetes, Metabolic Syndrome and Obesity;2024-01

2. Inhibiting SGLTs diminishes sympathetic output by reducing rostral ventrolateral medulla (RVLM) neuron activity;Hypertension Research;2023-11-22

3. Dapagliflozin treatment and cardiovascular outcome in RBP4/TTR^Val30Met (transthyretin cardiac amyloidosis) mice;ESC Heart Failure;2023-10-25

4. Insight on Cardiac Chronobiology and Latest Developments of Chronotherapeutic Antihypertensive Interventions for Better Clinical Outcomes;Current Hypertension Reviews;2023-08

5. Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action;Journal of Cardiovascular Development and Disease;2023-06-22